Phase III Randomized Trial Comparing Standard Care With and Without Stereotactic Ablative Radiotherapy
for Patients With Up to 10 Metastases and a Primary Tumor
Led by David Palma · Updated on 2025-12-31
180
Participants Needed
5
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating a phase III randomized trial comparing standard care treatment alone to standard care plus Stereotactic Ablative Radiotherapy SABR for patients with up to 10 oligometastases and a synchronous primary tumor. Patients are assigned in a 12 ratio to either receive palliative radiotherapy or a combination of standard care and SABR. Participants are stratified based on cancer histology and number of metastases to better understand treatment outcomes.
The trial includes two groups the standard arm receiving palliative radiotherapy aimed at symptom relief or preventing complications, and the experimental arm receiving treatment to both the primary tumor and metastases, with SABR preferred but other options like surgery, radiofrequency ablation, or fractionated radiation allowed if deemed better by oncologists. SABR doses typically range from 20 Gy in 1 fraction to 35 Gy in 5 fractions. Chemotherapy, hormone therapy, immunotherapy, targeted systemic therapy, or observation follow standard care approaches.
Participants will undergo restaging imaging, performance status assessments, and monitoring for adverse effects over approximately six years. Researchers will measure overall survival as the primary outcome, with secondary outcomes including quality of life evaluations using FACT-G and EQ-5D-5L questionnaires, toxicity assessments by CTCAE, time to next systemic therapy, and receipt of additional radiation. Safety follow-up and detailed quality of life data collection take place mainly during the first two years of the study.
CONDITIONS
Brief Title
A Randomized Phase III Trial of Stereotactic Ablative Radiotherapy for Patients With Up to 10 Oligometastases and a Synchronous Primary Tumor.
Research Team
D
David Palma, MD, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Histologically confirmed malignancy with metastatic disease detected on imaging
Total number of metastases between 1 and 10 at enrollment, with a primary tumor present
Restaging completed within 12 weeks prior to randomization
No computed tomography changes suggestive of fibrotic interstitial lung disease for patients receiving thoracic radiotherapy
10 or fewer lifetime metastases from the cancer for which enrolled
You will not qualify if you...
Serious medical conditions preventing radiotherapy, including interstitial lung disease, Crohn's disease, ulcerative colitis, lupus, or scleroderma
Moderate or severe liver dysfunction for patients with liver metastases
Substantial overlap with previously treated radiation volume
Malignant pleural effusion
Inability to treat all disease sites
Brain metastasis larger than 3 cm or total brain metastases volume over 30 cc
Metastasis in the brainstem
Evidence of spinal cord compression
Metastatic disease invading gastrointestinal tract or skin
Pregnant or lactating women
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Varies according to treatment plan and modalities used
Participants receive treatment to the primary tumor and metastases. Treatment options include stereotactic ablative radiotherapy (SABR), surgery, radiofrequency therapy (RFA), fractionated radiation, chemoradiation, or palliative radiotherapy depending on the assigned arm and treating oncologists' decisions. Systemic therapies such as chemotherapy, hormone therapy, immunotherapy, or targeted therapies may also be given based on standard care.
Visit frequency depends on treatment modality; includes radiation and systemic therapy visits as scheduled by the treatment team
Follow-up
Duration - Up to 6 years after randomization
Participants are monitored for quality of life, toxicity, and receipt of additional therapies after treatment completion.
Visits at 3, 6, 12, 18, and 24 months for quality of life and toxicity assessments; ongoing monitoring up to 6 years
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Phase I Study to Find the Best Dose of 5-Azacitidine with PD-1PD-L1 Inhibitors for Patients With Tumors Resistant to These Treatments
Phase I Study of CD70-targeted CAR-T Therapy for Adults with Advanced or Metastatic CD70-positive Solid Tumors
Phase III Randomized Trial Comparing Standard Care With and Without Stereotactic Ablative Radiotherapy
for Patients With Up to 10 Metastases and a Primary Tumor
Open-label Study to Evaluate Safety, Dosing, and Preliminary Anti-tumor Activity of Oral CDK2 Degrader NKT3964 Alone or with Chemotherapy in Adults with Advanced or Metastatic Solid Tumors
Phase 2 Study of Targeted Radiation Therapy for Patients With High-Risk Cancer Spread to the Spine
Study of Chemotherapy, Androgen-receptor Targeting Drugs, or Radiotherapy Combined With Hormone Therapy for Men With Metastatic Hormone-Sensitive Prostate Cancer in Italian Hospitals
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
A randomized phase III trial of stereotactic ablative radiotherapy for patients with up to 10 oligometastases and a synchronous primary tumor (SABR-SYNC): study protocol.
David A Palma, Meredith E Giuliani, Rohann J M Correa...